Learn why this royalty company believes it is the best way to play commodities and inflation. on 06/22/2021. Learn More

Streetwise Reports' Article Archives — April 2021 back to current month (20)

CryoLife Shares Trade 18% Higher on Q1 Financial Results (04/30/2021)

Shares of CryoLife Inc. set a new 52-week high intraday price after the company reported that total revenues in Q1/21 increased by 7% YoY to $71.1 million.

more>

Galera Posts Positive Data from Phase 1/2 Pancreatic Cancer Trial (04/29/2021)

Galera Therapeutics shares traded 25% higher after the company reported new data from its Phase 1/2 pilot study of dismutase mimetic GC4419 that when used in combination with radiation therapy was shown to nearly double median overall survival time in patients with locally advanced pancreatic cancer.

more>

Biopharma Study Shows Safety of Stem Cell Therapy in Severe COVID-19 Patients (04/28/2021)

The clinical trial, in which Sorrento Therapeutics established safety, and the company's next steps for this potential treatment are summarized in a Dawson James Securities report.

more>

Company Receives Its Largest Order for Antibiotic-Free Animal Feed Product (04/28/2021)

Avivagen Inc. reported it received a 4.4 metric tonne purchase order for OxC-beta Livestock from UNAHCO representing its largest single order to date.

more>

ADMA Biologics Granted FDA Approval to Boost IVIG Production by 50% (04/28/2021)

ADMA Biologics shares traded 9% higher after the company received FDA approval for increased intravenous immune globulin production scale, allowing the firm to increase manufacturing capacity from 400,000 to 600,000 liters and achieve peak revenues of greater than $300 million.

more>

Aldeyra's Drug Meets All Key Endpoints in Phase 3 Allergic Conjunctivitis Trial (04/27/2021)

Aldeyra Therapeutics shares traded 33% higher after the firm reported that reproxalap significantly met all primary and secondary endpoints in its Phase 3 allergic conjunctivitis study.

more>

Ocugen Reports $100 Million Direct Share Offering at Market Premium from Institutional Investors (04/23/2021)

Ocugen Inc. shares traded up as much as 47% before closing just 3.66% higher after the company announced a $100 million registered direct offering of common stock priced at a $10 per share, which represents a premium to the market price.

more>

Healthcare Services Group Shares Rise 13% on Q1 Earnings and Quarterly Dividend Increase (04/21/2021)

Healthcare Services Group Inc.'s shares traded 13% higher after the company reported Q1/21 financial results that included a 22% YoY increase in net income.

more>

Is the Trend Turning for This Psychedelic Stock? (04/19/2021)

Technical analyst Clive Maund charts Delic Inc. and explains why he considers the stock attractive at this point.

more>

Merck Selects Rapidly Growing Psychedelic Medicine Company as Key Research Site (04/16/2021)

Novamind runs clinics, research sites and therapeutic retreats and is positioning itself for expansion.

more>

Health Tech Company Acquiring Ontario Health Management Firm, Its Largest Transaction Ever (04/16/2021)

A Research Capital Corp. report discusses CloudMD Software & Services' acquisition of Oncidium, "one of Canada's leading health management companies."

more>

Ardelyx to Receive $5M Milestone Payment as Japan Partner Initiates Phase 3 (04/15/2021)

Ardelyx Inc. shares traded 11% higher after Kyowa Kirin Co. Ltd., its collaborative partner in Japan, initiated four Phase 3 clinical trials of tenapanor for treatment of hyperphosphatemia.

more>

Biotech Company Acquires Therapeutics Firm, Gains 'Gem' in the Portfolio (04/14/2021)

Dawson James Securities advised it is maintaining its "Buy" rating after Sorrento Therapeutics announced the acquisition of ACEA Therapeutics for $38 million in stock.

more>

Novocure Shares Climb 50% on Acceleration of Phase 3 Lung Cancer Trial (04/13/2021)

Novocure Ltd. shares reached a new 52-week high after the company reported an update from its Phase 3 Pivotal LUNAR trial of tumor treating electrical fields in non-small cell lung cancer.

more>

Affimed NV Shares Rise 20% on Initial Data from Phase 1 R/R CD30-Positive Lymphoma Trial (04/09/2021)

Affimed NV shares reached a new 52-week high price after the company presented initial data from a Phase 1 trial of its AFM13 that shows potential to help NK cells target and destroy cancer cells.

more>

Gene Therapy Restoring Light Sensitivity 'Showed Impressive Dose-Response Improvements' (04/07/2021)

Roth Capital Partners advised that Applied Genetic Technologies co-development of BS01 with Bionic Sight "validates its gene therapy capabilities."

more>

Biopharma's Phase 2b/3 Alzheimer's Disease Trial Approved to Continue (04/07/2021)

Anavex Life Sciences' study, its drug's mechanism of action and the company's upcoming catalysts are covered in a Dawson James Securities report.

more>

Biohaven Expects Net Revenue of $43.8 Million in Q1 for Its Migraine Medicine (04/07/2021)

Biohaven Pharmaceutical shares traded 10% higher after the company reported that in Q1/21 net product revenue for its migraine drug NURTEC ODT is estimated to be approximately $43.8 million.

more>

Nano-X Imaging Receives Go Ahead from FDA for Single Source Digital X-Ray (04/05/2021)

Shares of Nano-X Imaging Ltd. traded 17% higher after the company reported that the FDA has granted 510(k) approval for its single source ARC digital x-ray.

more>

United Therapeutics Shares Rise 15% as FDA Clears Pathway to Launch Tyvaso to Treat PH-ILD (04/01/2021)

United Therapeutics shares reached a new 52-week high after the firm reported that the U.S. FDA granted approval to commercially launch its TyvasoŽ Inhalation Solution to treat patients with pulmonary hypertension associated with interstitial lung disease.

more>

More Archives

2021May Apr Mar Feb Jan

2020Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2019Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2018Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2017Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2016Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

Notable Quotes

"Momentum continues to build for VIV."
– Joseph Gomes, Wm Smith & Co.